Design Therapeutics (NASDAQ:DSGN - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04, Zacks reports.
Design Therapeutics Stock Performance
NASDAQ DSGN traded down $0.05 during trading on Monday, reaching $4.87. The company's stock had a trading volume of 111,609 shares, compared to its average volume of 183,138. The firm has a market cap of $275.74 million, a price-to-earnings ratio of -5.73 and a beta of 1.77. Design Therapeutics has a twelve month low of $2.45 and a twelve month high of $7.77. The business's fifty day moving average price is $4.87 and its 200-day moving average price is $5.36.
Design Therapeutics Company Profile
(
Get Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Stories
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
